Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Prostate Cancer

  Free Subscription


Articles published in Proc Natl Acad Sci U S A

Retrieve available abstracts of 40 articles:
HTML format



Single Articles


    July 2020

  1. Correction to Supporting Information for Zadra et al., Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2020 Jul 27. pii: 2012767117.
    PubMed    


    June 2020
  2. BICAK M, Luckerath K, Kalidindi T, Phelps ME, et al
    Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted alpha-particle therapy.
    Proc Natl Acad Sci U S A. 2020 Jun 12. pii: 1918744117.
    PubMed     Abstract available


  3. ALUMKAL JJ, Sun D, Lu E, Beer TM, et al
    Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.
    Proc Natl Acad Sci U S A. 2020;117:12315-12323.
    PubMed     Abstract available


    May 2020
  4. LU WC, Saha A, Yan W, Garrison K, et al
    Enzyme-mediated depletion of serum l-Met abrogates prostate cancer growth via multiple mechanisms without evidence of systemic toxicity.
    Proc Natl Acad Sci U S A. 2020 May 20. pii: 1917362117.
    PubMed     Abstract available


    April 2020
  5. HALDAR S, Mishra R, Billet S, Thiruvalluvan M, et al
    Cancer epithelia-derived mitochondrial DNA is a targetable initiator of a paracrine signaling loop that confers taxane resistance.
    Proc Natl Acad Sci U S A. 2020;117:8515-8523.
    PubMed     Abstract available


  6. WASMUTH EV, Hoover EA, Antar A, Klinge S, et al
    Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG.
    Proc Natl Acad Sci U S A. 2020;117:8584-8592.
    PubMed     Abstract available


    March 2020
  7. PHILLIPS JW, Pan Y, Tsai BL, Xie Z, et al
    Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers.
    Proc Natl Acad Sci U S A. 2020;117:5269-5279.
    PubMed     Abstract available


    February 2020
  8. PIETRZAK K, Kuzyakiv R, Simon R, Bolis M, et al
    TIP5 primes prostate luminal cells for the oncogenic transformation mediated by PTEN-loss.
    Proc Natl Acad Sci U S A. 2020;117:3637-3647.
    PubMed     Abstract available


    January 2020
  9. HSU EC, Rice MA, Bermudez A, Marques FJG, et al
    Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
    Proc Natl Acad Sci U S A. 2020 Jan 13. pii: 1905384117.
    PubMed     Abstract available


    October 2019
  10. MOPARTHI L, Pizzolato G, Koch S
    Wnt activator FOXB2 drives the neuroendocrine differentiation of prostate cancer.
    Proc Natl Acad Sci U S A. 2019 Oct 14. pii: 1906484116.
    PubMed     Abstract available


    July 2019
  11. JAILKHANI N, Ingram JR, Rashidian M, Rickelt S, et al
    Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix.
    Proc Natl Acad Sci U S A. 2019;116:14181-14190.
    PubMed     Abstract available


  12. GUI B, Gui F, Takai T, Feng C, et al
    Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Proc Natl Acad Sci U S A. 2019 Jul 2. pii: 1908547116.
    PubMed     Abstract available


    June 2019

  13. Correction for Geng et al., Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
    Proc Natl Acad Sci U S A. 2019 Jun 24. pii: 1908767116.
    PubMed    



  14. Correction for Lorenzo et al., Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth.
    Proc Natl Acad Sci U S A. 2019 Jun 10. pii: 1908514116.
    PubMed    


    May 2019
  15. MA X, Huang J
    Predicting clinical outcome of therapy-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2019 May 21. pii: 1906812116.
    PubMed    


  16. STOPSACK KH, Whittaker CA, Gerke TA, Loda M, et al
    Aneuploidy drives lethal progression in prostate cancer.
    Proc Natl Acad Sci U S A. 2019 May 13. pii: 1902645116.
    PubMed     Abstract available


  17. ABIDA W, Cyrta J, Heller G, Prandi D, et al
    Genomic correlates of clinical outcome in advanced prostate cancer.
    Proc Natl Acad Sci U S A. 2019 May 6. pii: 1902651116.
    PubMed     Abstract available


    March 2019
  18. ZHENG Y, Comaills V, Burr R, Boulay G, et al
    COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis.
    Proc Natl Acad Sci U S A. 2019;116:5223-5232.
    PubMed     Abstract available


  19. PRADHAN AK, Bhoopathi P, Talukdar S, Scheunemann D, et al
    MDA-7/IL-24 regulates the miRNA processing enzyme DICER through downregulation of MITF.
    Proc Natl Acad Sci U S A. 2019;116:5687-5692.
    PubMed     Abstract available


    January 2019
  20. LORENZO G, Hughes TJR, Dominguez-Frojan P, Reali A, et al
    Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth.
    Proc Natl Acad Sci U S A. 2019 Jan 7. pii: 1815735116.
    PubMed     Abstract available


    December 2018
  21. ZADRA G, Ribeiro CF, Chetta P, Ho Y, et al
    Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2018 Dec 21. pii: 1808834116.
    PubMed     Abstract available


    November 2018
  22. FONG LY, Jing R, Smalley KJ, Wang ZX, et al
    Human-like hyperplastic prostate with low ZIP1 induced solely by Zn deficiency in rats.
    Proc Natl Acad Sci U S A. 2018;115:E11091-E11100.
    PubMed     Abstract available


    October 2018
  23. GARRIGUE P, Tang J, Ding L, Bouhlel A, et al
    Self-assembling supramolecular dendrimer nanosystem for PET imaging of tumors.
    Proc Natl Acad Sci U S A. 2018 Oct 22. pii: 1812938115.
    PubMed     Abstract available


  24. ARORA H, Panara K, Kuchakulla M, Kulandavelu S, et al
    Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth.
    Proc Natl Acad Sci U S A. 2018 Oct 15. pii: 1812704115.
    PubMed     Abstract available


  25. FENG S, Cheng X, Zhang L, Lu X, et al
    Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers.
    Proc Natl Acad Sci U S A. 2018;115:10094-10099.
    PubMed     Abstract available


    September 2018

  26. Correction for Chen et al., Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
    Proc Natl Acad Sci U S A. 2018;115:E9025.
    PubMed    


    August 2018
  27. DUDANI JS, Ibrahim M, Kirkpatrick J, Warren AD, et al
    Classification of prostate cancer using a protease activity nanosensor library.
    Proc Natl Acad Sci U S A. 2018 Aug 20. pii: 1805337115.
    PubMed     Abstract available


    June 2018
  28. NAVARRO HI, Goldstein AS
    HoxB13 mediates AR-V7 activity in prostate cancer.
    Proc Natl Acad Sci U S A. 2018 Jun 11. pii: 1808196115.
    PubMed    


    May 2018
  29. CHEN Z, Wu D, Thomas-Ahner JM, Lu C, et al
    Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
    Proc Natl Acad Sci U S A. 2018 May 29. pii: 1718811115.
    PubMed     Abstract available


    April 2018
  30. FAN L, Zhang F, Xu S, Cui X, et al
    Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells.
    Proc Natl Acad Sci U S A. 2018 Apr 30. pii: 1802415115.
    PubMed     Abstract available


  31. TAKAYAMA KI, Suzuki T, Fujimura T, Takahashi S, et al
    COBLL1 modulates cell morphology and facilitates androgen receptor genomic binding in advanced prostate cancer.
    Proc Natl Acad Sci U S A. 2018 Apr 23. pii: 1721957115.
    PubMed     Abstract available


  32. LEE JK, Bangayan NJ, Chai T, Smith BA, et al
    Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.
    Proc Natl Acad Sci U S A. 2018 Apr 23. pii: 1802354115.
    PubMed     Abstract available


  33. ELLIS L, Loda M
    LSD1: A single target to combat lineage plasticity in lethal prostate cancer.
    Proc Natl Acad Sci U S A. 2018 Apr 16. pii: 1804205115.
    PubMed    


  34. POWELL GRAY B, Kelly L, Ahrens DP, Barry AP, et al
    Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.
    Proc Natl Acad Sci U S A. 2018 Apr 16. pii: 1717705115.
    PubMed     Abstract available


    March 2018
  35. SEHRAWAT A, Gao L, Wang Y, Bankhead A 3rd, et al
    LSD1 activates a lethal prostate cancer gene network independently of its demethylase function.
    Proc Natl Acad Sci U S A. 2018 Mar 26. pii: 1719168115.
    PubMed     Abstract available


    February 2018
  36. HASHIMOTO K, Ochi H, Sunamura S, Kosaka N, et al
    Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A.
    Proc Natl Acad Sci U S A. 2018;115:2204-2209.
    PubMed     Abstract available


    October 2017
  37. KUNDU M, Roy A, Pahan K
    Selective neutralization of IL-12 p40 monomer induces death in prostate cancer cells via IL-12-IFN-gamma.
    Proc Natl Acad Sci U S A. 2017;114:11482-11487.
    PubMed     Abstract available


    September 2017
  38. TAKAYAMA KI, Suzuki T, Fujimura T, Yamada Y, et al
    Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF.
    Proc Natl Acad Sci U S A. 2017 Sep 11. pii: 201706076.
    PubMed     Abstract available


    June 2017
  39. FEI T, Chen Y, Xiao T, Li W, et al
    Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.
    Proc Natl Acad Sci U S A. 2017 Jun 13. pii: 201617467.
    PubMed     Abstract available


    May 2017

  40. Correction for Dash et al., Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity.
    Proc Natl Acad Sci U S A. 2017 May 22. pii: 201706353.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: